Bronchiectasis

• The vicious cycle of infection and inflammation: The disease initiates when initial insults (infection, aspiration, obstruction, or genetic abnormality) damage the bronchial epithelium and impair mucociliary clearance. Compromised clearance allows bacteria to colonize the airways; common colonizing organisms include Haemophilus influenzae, Streptococcus pneumoniae, Pseudomonas aeruginosa, and atypical mycobacteria (Mycobacterium avium complex). These pathogens trigger robust neutrophilic inflammation with release of proteolytic enzymes (particularly neutrophil elastase and matrix metalloproteinases) that degrade the structural proteins of the bronchial wall—elastin, collagen, and the smooth muscle layer. This enzymatic destruction directly causes bronchial dilatation; simultaneously, the impaired airway clearance perpetuates bacterial colonization, sustaining chronic infection and continued enzyme release. The result is progressive, irreversible bronchial dilatation that worsens airway obstruction and stasis, completing the pathologic cycle. The defining imaging ratio is the bronchus-to-artery ratio >1 (normally the bronchus is smaller than the accompanying artery), and bronchial wall thickening reflects chronic inflammation and fibrosis.

• Abnormal mucociliary clearance as central mechanism: Normal mucociliary clearance depends on intact ciliary function, appropriate mucus rheology, and adequate airway caliber. In bronchiectasis, one or more components fail: primary ciliary dyskinesia features structurally abnormal cilia with impaired beating; cystic fibrosis produces abnormally viscous secretions despite normal cilia; acquired causes of bronchiectasis (post-infection, post-aspiration) often develop localized areas of epithelial loss and ciliary damage. Impaired clearance leads to mucus stasis, bacterial overgrowth, and chronic inflammation. The accumulation of purulent secretions within dilated airways explains the prominent productive cough and predisposes to superimposed acute infections.

• Bronchial wall structural destruction and architectural abnormalities: The elastic lamina and muscular layer of bronchial walls are progressively destroyed by chronic inflammation and proteolytic enzymes. Three morphologic patterns of bronchiectasis are recognized and reflect the degree of bronchial dilatation and destruction: cylindrical bronchiectasis shows uniform dilatation without marked loss of the normal bronchial taper; varicose bronchiectasis features a beaded appearance with alternating areas of dilatation and narrowing, indicating more severe wall damage; saccular (or cystic) bronchiectasis displays large cyst-like dilations at the bronchial termini, representing the most severe form of wall destruction. Saccular bronchiectasis is most common in lower lobes and particularly associated with poor prognosis. Loss of structural support also impairs the normal expiratory narrowing of airways, contributing to air trapping and obstructive physiology.

• Genetic and immunologic predisposition mechanisms: Certain genetic abnormalities directly predispose to bronchiectasis by impairing critical host defenses. Cystic fibrosis, the most common genetic cause in developed nations, results from mutations in the CFTR gene (cystic fibrosis transmembrane conductance regulator), which encodes a chloride channel essential for regulating hydration of airway secretions; CFTR dysfunction leads to viscous secretions, impaired clearance, and bronchiectasis in nearly all CF patients. Primary ciliary dyskinesia (immotile cilia syndrome) is caused by genetic mutations affecting ciliary structure or dynein arm function, resulting in ineffective mucociliary clearance; approximately 50% of patients develop bronchiectasis. Immunoglobulin deficiencies (hypogammaglobulinemia, selective IgA deficiency) impair opsonization and bacterial killing, predisposing to recurrent infections. Complement deficiencies similarly compromise bacterial opsonization. These genetic/immunologic factors lower the threshold for infection-driven bronchiectasis initiation.

• Airway obstruction as initiating factor: Post-obstructive bronchiectasis develops distal to sites of chronic obstruction (tumors, foreign bodies, mucus plugging in asthma). Obstruction causes distal airway collapse during expiration, preventing effective airway clearance and leading to chronic distal infection. The obstruction physically prevents normal airflow patterns that normally contribute to clearance, perpetuating downstream infection and inflammation.

• Defective inflammatory resolution and tissue remodeling: Beyond acute inflammatory responses, bronchiectasis is characterized by abnormal resolution of inflammation. Excessive and prolonged neutrophilic infiltration, combined with impaired epithelial repair mechanisms, leads to chronic airway wall fibrosis and remodeling. Fibrosis further impairs mucociliary clearance and contributes to the irreversibility of structural changes.

• Cystic fibrosis (CF): CF is the leading genetic cause of bronchiectasis in most developed countries and accounts for approximately 10-15% of bronchiectasis cases overall. The condition is progressive; nearly all CF patients develop bronchiectasis by adulthood if they survive long enough. CF-related bronchiectasis typically involves the upper lobes preferentially (in contrast to non-CF bronchiectasis which favors lower lobes), though distribution varies. Management of CF-related bronchiectasis requires specific CF-focused therapies including CFTR modulators (ivacaftor, lumacaftor, elexacaftor-tezacaftor-ivacaftor), aggressive airway clearance, and pancreatic enzyme replacement.

• Chronic obstructive pulmonary disease (COPD) and emphysema: COPD is a frequent comorbid condition and risk factor for bronchiectasis, particularly in patients with severe emphysema. The mechanisms likely involve impaired local immunity, abnormal inflammatory responses, and airway obstruction with distal infection. Some patients develop "combined pulmonary fibrosis and emphysema" with bronchiectasis, a particularly severe phenotype. Bronchiectasis in COPD patients is associated with worse outcomes and more frequent exacerbations compared to COPD alone.

• Asthma, particularly severe/difficult-to-treat asthma: Allergic bronchopulmonary aspergillosis (ABPA) is a form of asthma associated with allergic response to Aspergillus fumigatus colonization that directly causes bronchiectasis; patients present with asthma, pulmonary infiltrates, elevated IgE, and *Aspergillus*-specific antibodies. The aspergillus colonization triggers a hypersensitivity response rather than typical infection. More broadly, severe asthma patients without ABPA demonstrate increased bronchiectasis prevalence, suggesting asthma-related airway remodeling and inflammation predispose to bronchiectasis development. The airway hyperresponsiveness and chronic inflammation of asthma may impair normal clearance mechanisms or promote secondary infection.

• Primary ciliary dyskinesia (PCD): PCD is an autosomal recessive condition affecting ciliary structure or function, present in approximately 1 in 15,000-20,000 live births. Symptoms typically present in childhood with chronic wet cough, recurrent otitis media, and chronic rhinosinusitis; bronchiectasis develops in 50-90% of patients. Kartagener syndrome is the subset of PCD patients with situs inversus totalis (about 50% of PCD cases). Diagnosis is confirmed by high-speed video microscopy analysis of ciliary beat pattern, nasal nitric oxide measurement, and/or genetic testing. Management focuses on aggressive airway clearance and infection prevention.

• Immunodeficiency disorders: These are crucial to screen for in newly diagnosed bronchiectasis. Common variable immunodeficiency (CVID) features hypogammaglobulinemia with markedly reduced immunoglobulin levels and impaired specific antibody responses to vaccines; patients develop recurrent sino-pulmonary infections and bronchiectasis. Selective IgA deficiency is the most common primary immunodeficiency but most patients remain asymptomatic; symptomatic individuals develop recurrent infections and bronchiectasis. X-linked agammaglobulinemia presents in young boys with absent B cells and hypogammaglobulinemia. Complement deficiencies (particularly C3, C5-9) impair opsonization and bacterial killing. Job syndrome (STAT3 mutations) features immune dysregulation with recurrent skin and lung infections. These conditions require immunoglobulin replacement therapy and sometimes prophylactic antibiotics; bronchiectasis management is complicated by ongoing immunodeficiency.

• **Non-tuberculous mycobacteria (NTM), particularly Mycobacterium avium complex (MAC)**: NTM, especially MAC, are increasingly recognized as both cause and consequence of bronchiectasis. MAC preferentially colonizes dilated airways in patients with pre-existing bronchiectasis (particularly affecting older women with no prior lung disease—the "MAC lady" phenotype), creating a challenging treatment scenario. The distinction between infection and colonization is clinically important: colonization (positive culture without clinical symptoms or radiographic progression) requires observation, while true infection (positive culture plus symptoms and radiographic changes) warrants treatment with multidrug regimens. The risk of NTM infection increases in bronchiectasis patients due to impaired local immunity and chronic inflammation creating a permissive environment.

• Recurrent or chronic respiratory infections: Severe childhood pneumonias (particularly those caused by Staphylococcus aureus, Klebsiella pneumoniae, or Mycobacterium tuberculosis) can directly destroy bronchial architecture and initiate bronchiectasis. In developing countries, tuberculosis is a leading cause of bronchiectasis; typically causes mid-zone involvement. Whooping cough (Bordetella pertussis) in infants can cause bronchial damage and subsequent bronchiectasis. Measles and adenovirus infections in childhood are historical causes, now rare in vaccinated populations.

• Aspiration disorders and chronic aspiration: Chronic aspiration of oral contents (from swallowing dysfunction, achalasia, gastroesophageal reflux disease, or neurologic disorders) introduces both mechanical obstruction and pathogenic bacteria into distal airways, causing post-obstructive bronchiectasis and chronic infection. Aspiration is particularly common in patients with neurologic diseases (cerebral palsy, Parkinson disease, amyotrophic lateral sclerosis). The right lower lobe is most commonly affected due to gravitational factors and the angle of the right mainstem bronchus.

• Airway obstruction (post-obstructive bronchiectasis): Any chronic obstruction of a bronchus can lead to distal bronchiectasis. Etiologies include endobronchial tumors, foreign body aspiration (particularly in children), bronchial stenosis, lymph node compression, and severe bronchial asthma with chronic mucus plugging. The obstruction prevents normal airflow and clearance of distal secretions, leading to chronic infection and inflammation distal to the obstruction site.

• Connective tissue diseases: Rheumatoid arthritis (RA) is associated with bronchiectasis in 5-10% of cases, sometimes predating articular manifestations; the mechanism may involve abnormal local immunity, vasculitis, or direct lung inflammation. Sjögren syndrome features immune-mediated destruction of exocrine glands including airway epithelium, predisposing to bronchiectasis. Systemic lupus erythematosus (SLE), dermatomyositis, and inflammatory bowel disease are less commonly associated but should be screened for in appropriate clinical contexts. These connective tissue disorders cause bronchiectasis through mechanisms involving systemic inflammation, autoimmune-mediated airway damage, and/or associated immunodeficiency.

• Alpha-1 antitrypsin (AAT) deficiency: AAT is a serum protease inhibitor that protects lung tissue from neutrophil elastase; deficiency leads to progressive emphysema and COPD, frequently with associated bronchiectasis. Patients with AAT deficiency PiZZ phenotype (most severe, with AAT levels <57 mg/dL) develop premature emphysema and bronchiectasis, particularly with tobacco exposure. Diagnosis is confirmed by low AAT serum level and Pi typing. AAT replacement therapy can slow disease progression if initiated before severe lung disease develops.

• Idiopathic bronchiectasis: After appropriate investigation, 40-50% of bronchiectasis cases remain idiopathic with no identifiable underlying cause. This diagnosis should be made only after excluding CF, immunodeficiency, PCD, NTM infection, aspiration, asthma/ABPA, prior tuberculosis, and other secondary causes. Idiopathic bronchiectasis may represent unrecognized prior infections, occult immunodeficiency, or primary airway ciliary dysfunction beyond current diagnostic capability.

• Productive cough as cardinal symptom: Chronic productive cough is the hallmark feature, present in >90% of symptomatic patients. The cough reflects impaired mucociliary clearance and chronic bacterial colonization; patients expectorate large volumes of purulent sputum (often >30 mL daily, sometimes exceeding 100-200 mL/day in severe cases). Sputum is typically greenish or yellowish, reflecting chronic suppuration and inflammatory cell infiltration. The cough is persistent year-round but often worsens in winter months or with upper respiratory infections. Patients develop distinct morning cough patterns related to overnight secretion accumulation. The volume and character of sputum do not always correlate with disease severity as measured by imaging or pulmonary function tests. Some patients with mild disease may have scant sputum production while others develop massive daily expectoration.

• Dyspnea and exercise limitation: Dyspnea severity correlates with extent of bronchiectasis, severity of airway obstruction, and degree of hypoxemia. Patients develop dyspnea on exertion proportional to the FEV₁ and extent of bronchial involvement. Mechanism includes obstructive physiology (air trapping, altered mechanics), loss of functional lung units, and accompanying emphysema in COPD-related cases. Severe bronchiectasis can progress to dyspnea at rest, particularly during acute exacerbations.

• Recurrent or persistent respiratory infections: Exacerbations occur when colonizing bacteria proliferate in response to viral infections, environmental triggers, or spontaneously. Acute exacerbations are defined by increased sputum purulence, increased sputum volume, fever, and constitutional symptoms; they typically occur 2-4 times annually in moderate-to-severe disease and may be more frequent in winter. Exacerbations drive disease progression through acute inflammation and airway damage. Some patients experience almost continuous symptoms due to high bacterial burden, blurring the distinction between exacerbations and baseline disease.

• Hemoptysis: Hemoptysis occurs in 20-50% of bronchiectasis patients, ranging from minor streaking of sputum to massive life-threatening bleeding. The mechanism involves erosion of dilated bronchial arteries within the bronchial wall; bronchiectatic airways are supplied by hypertrophied bronchial circulation (normal bronchial arteries supply <5% of pulmonary blood flow, but in severe bronchiectasis may contribute substantially to pulmonary blood perfusion). Minor hemoptysis is typically self-limited and requires observation; massive hemoptysis (>240 mL in 24 hours) is a medical emergency

Step 1 — initial imaging

• Chest radiograph: cheap and fast but insensitive; may show tram-track lines (parallel thickened bronchial walls), ring shadows, or crowded vessels. A normal film does not exclude the diagnosis.

Step 2 — confirmatory (gold standard)

• Thin-section, non-contrast high-resolution CT (HRCT) of the chest: the diagnostic reference standard in both the European Respiratory Society and British Thoracic Society adult bronchiectasis guidelines, which are the documents US clinicians follow in the absence of a distinct American bronchiectasis guideline. Diagnostic findings:
• Bronchus-to-artery ratio >1 (signet ring sign) — the dilated bronchus and its adjacent pulmonary artery seen in cross-section.
• Lack of normal distal tapering of the bronchus over its course.
• Airways visible within roughly 1 cm of the pleural surface or abutting the mediastinal pleura.
• Ancillary: bronchial wall thickening, mucus plugging with tree-in-bud opacities, mosaic attenuation from small-airway obstruction.
• Lobar distribution guides etiology: upper-lobe predominance suggests cystic fibrosis or ABPA, right middle lobe/lingula suggests Mycobacterium avium complex, and focal disease demands bronchoscopy to exclude tumor or aspirated foreign body.

Step 3 — etiologic workup (ERS/BTS minimum bundle)

• Sputum culture for routine bacteria plus acid-fast bacilli and fungal culture; CBC with differential; serum IgG, IgA, IgM (screening for common variable immunodeficiency); total IgE with Aspergillus-specific IgE/precipitins for ABPA; sweat chloride and CFTR genotyping when age, upper-lobe disease, malabsorption, infertility, or Staphylococcus aureus isolation suggest cystic fibrosis; alpha-1 antitrypsin level; RF/anti-CCP when arthritis is present; nasal nitric oxide or ciliary/genetic testing for primary ciliary dyskinesia.
• Spirometry typically shows an obstructive pattern (reduced FEV₁/FVC) and is used for longitudinal monitoring.

Severity scoring

• Bronchiectasis Severity Index (BSI) and the FACED score stratify mortality and exacerbation risk using elements such as age, FEV₁, BMI, prior hospitalization, radiographic extent, and Pseudomonas aeruginosa colonization.

Acute exacerbation (immediate management)

• Send sputum culture before antibiotics, then treat empirically based on the patient's prior isolates — the approach endorsed by the European Respiratory Society and British Thoracic Society adult bronchiectasis guidelines. A roughly 14-day course is standard, longer than for uncomplicated bronchitis.
• No prior Pseudomonas: aminopenicillin/beta-lactamase inhibitor (amoxicillin-clavulanate) covering Haemophilus influenzae and Streptococcus pneumoniae.
• **Known *Pseudomonas aeruginosa***: antipseudomonal fluoroquinolone (ciprofloxacin) orally, or IV antipseudomonal beta-lactam (piperacillin-tazobactam, ceftazidime, cefepime) if severely ill.
• **First isolation of *P. aeruginosa* should prompt an eradication attempt** (oral ciprofloxacin ± inhaled antipseudomonal), since chronic colonization independently predicts mortality.

Chronic maintenance — foundation of care

• Airway clearance: daily chest physiotherapy, active cycle of breathing, oscillatory PEP devices — the single most important non-pharmacologic intervention.
• Nebulized hypertonic saline as a mucoactive agent; pretreat with a short-acting beta-agonist to prevent bronchospasm.
• Pulmonary rehabilitation and vaccination (annual influenza, pneumococcal, COVID-19) per ACIP schedules.

Escalation for frequent exacerbations (generally ≥3/year)

• Long-term macrolide: azithromycin, which is anti-inflammatory as well as antimicrobial. Exclude non-tuberculous mycobacterial infection first — macrolide monotherapy in unrecognized NTM breeds macrolide resistance. Check baseline ECG (QT) and hearing.
• Inhaled antibiotics (tobramycin, colistin, aztreonam) for chronic Pseudomonas — recommended by ERS, though not FDA-approved for non-CF bronchiectasis in the US.
• Treat the underlying cause: IgG replacement in CVID, CFTR modulators (elexacaftor-tezacaftor-ivacaftor) in cystic fibrosis, systemic corticosteroids ± itraconazole for ABPA, multidrug macrolide-based regimens for true MAC disease per the ATS/ERS/ESCMID/IDSA nontuberculous mycobacteria guideline.

Definitive/procedural

• Bronchial artery embolization for massive hemoptysis; surgical resection (lobectomy/segmentectomy) for localized, refractory disease or uncontrolled bleeding; lung transplantation for end-stage disease.

Contraindicated/avoid

• Recombinant human DNase (dornase alfa): beneficial in cystic fibrosis but associated with worse outcomes in non-CF bronchiectasis — do not use.
• Routine inhaled corticosteroids are not indicated unless asthma, ABPA, or COPD overlap coexists; they raise pneumonia and mycobacterial risk.
• Avoid cough suppressants, which defeat clearance.

Emergencies

• Massive hemoptysis (>240 mL/24 h): chronically inflamed airways recruit and hypertrophy bronchial arteries, which carry systemic arterial pressure; erosion into an airway produces brisk bleeding. Death is from asphyxiation, not exsanguination. Management: secure the airway, place the bleeding lung dependent (bleeding side down) to protect the healthy lung, correct coagulopathy, and proceed to bronchial artery embolization; surgery if embolization fails.
• Acute-on-chronic respiratory failure: severe exacerbation superimposed on obstructive physiology; signaled by rising PaCO₂, altered mental status, and accessory muscle use.
• Tension pneumothorax from rupture of a subpleural cystic/saccular airway — sudden pleuritic pain, hypotension, tracheal deviation.

Disease complications

• **Chronic Pseudomonas aeruginosa colonization**: mucoid biofilm phenotype, accelerated FEV₁ decline, more hospitalizations; a component of the Bronchiectasis Severity Index.
• Superimposed NTM or ABPA: suspect when a stable patient declines despite adherent therapy; new cavitation or tree-in-bud on CT, or rising IgE with mucus plugging, respectively.
• Cor pulmonale: chronic hypoxic pulmonary vasoconstriction raises pulmonary vascular resistance; look for elevated JVP, hepatomegaly, peripheral edema, and RV strain on ECG.
• Secondary (AA) amyloidosis: sustained serum amyloid A production from chronic suppuration; presents with proteinuria/nephrotic syndrome and renal failure. Rare, but a classic examination association.
• Lung abscess/empyema and anemia of chronic disease; digital clubbing marks longstanding suppuration.

Treatment complications

• Chronic azithromycin: QT prolongation with torsades risk, sensorineural hearing loss, and induction of macrolide-resistant NTM if NTM was not excluded first.
• Aminoglycosides (inhaled/IV tobramycin, amikacin): nephrotoxicity and irreversible vestibulocochlear toxicity.
• Fluoroquinolones: tendinopathy/rupture, aortic aneurysm-dissection risk, QT prolongation, Clostridioides difficile colitis.
• Nebulized hypertonic saline or inhaled antibiotics: acute bronchospasm — pretreat with a bronchodilator.
• Inhaled corticosteroids: increased pneumonia and mycobacterial infection risk, plus oral candidiasis.

• The imaging buzzwords: signet ring sign (bronchus-to-artery ratio >1), tram-track lines, lack of distal tapering, and tree-in-bud mucus plugging. Chronic daily purulent sputum + recurrent same-lobe pneumonia → best next step is HRCT chest, not another chest radiograph.
• Lobar distribution is the examiner's shortcut: upper lobes → cystic fibrosis or ABPA; right middle lobe/lingula in a thin elderly nonsmoking woman → Lady Windermere syndrome from Mycobacterium avium complex; lower lobes → idiopathic, aspiration, or immunodeficiency; mid-zone → prior tuberculosis.
• Central bronchiectasis + asthma + markedly elevated total IgE + eosinophilia = ABPA; treat with systemic corticosteroids ± itraconazole, not antibiotics.
• Situs inversus + chronic sinusitis + bronchiectasis = Kartagener syndrome; add male infertility from immotile sperm and neonatal respiratory distress. Screen with nasal nitric oxide (low).
• The one association examiners love: chronic Pseudomonas aeruginosa colonization predicts more exacerbations, faster FEV₁ decline, and higher mortality — first isolation should trigger an eradication attempt, not observation.
• Before starting chronic azithromycin, culture sputum for acid-fast bacilli. Macrolide monotherapy in occult NTM generates macrolide resistance and forfeits the drug that anchors MAC therapy.
• The classic distractor: dornase alfa (recombinant DNase). It helps in cystic fibrosis but is associated with worse outcomes in non-CF bronchiectasis — a wrong answer whenever the stem specifies non-CF disease. Likewise, inhaled corticosteroids are not routine unless asthma/ABPA/COPD overlap is present.
• Massive hemoptysis comes from hypertrophied bronchial (systemic) arteries, not the pulmonary circulation. Position the bleeding side down, protect the airway, and go to bronchial artery embolization — not to immediate lobectomy.
• Adults with newly diagnosed bronchiectasis deserve a minimum etiologic workup (immunoglobulins, IgE/Aspergillus serology, sputum AFB, CFTR testing when clinically suggested); roughly half remain idiopathic.